#109 Israeli biotech company MSL Pharma is looking for Dutch investors for two R&D projects
- Industry Life sciences and health
- Online since 2020-10-27
The Israeli biotech company MSL Pharma is looking for Dutch investors for two R&D projects, one for the treatment of obesity and metabolic syndromes and the second for early detection and treatment of cancer.
The Israeli biotech company MSL Pharma is looking for investors for two R&D projects:
1. an oral melanocortin 4 & 5 analogue for the treatment of obesity and metabolic syndromes (type 2 diabetes, hypertension, dyslipidemia) in order to prevent heart attacks, strokes and cirrhosis. This drug inhibits appetite and increases energy expenditure and lipolysis and by that facilitate the burning of calories. The project is at seed stage.
2. a multi-targeted drug delivery technology for the early detection and treatment of different forms of cancer. This technology prevents side effects of chemotherapeutic drugs, allows using a higher dosage of the drugs for better killing of the cancer cells, prevents and reverses drug resistance. Using a few drugs together allows complementary and synergistic effects of the drugs which enhances the killing of the tumor cells. The company has a novel smart multi-armed linker which can bind up to three payloads, releases the drugs and fluorescent only in the tumor cells, then they become active. A patent for the novel linker was already granted in the US. The linker can be used for Peptide drug Conjugates, Antibody Drug Conjugates and Nanoparticle drug Conjugates.
Interested? Contact Dr. Yarom Cohen at yarom@msl-pharma.com.
https://www.linkedin.com/posts/racheli-kreisberg-phd-mba-75b5284b_pharma-activity-6727100130513702912-Jliz
Go to website